Browsing Tag
GLP-1 drugs
6 posts
From AI to weight loss drugs, what Super Bowl LX ads reveal about the next legitimacy war
Super Bowl LX ads from AI platforms and GLP-1 drugmakers reveal how trust, not technology, is shaping the next growth cycle. Read the full analysis.
Novo Nordisk’s Alzheimer’s treatment hopes crash as semaglutide fails to slow cognitive decline
Novo Nordisk’s GLP-1 pill failed in Alzheimer’s trials, raising questions on neurology diversification. Read what this means for its pipeline and stock.
Wegovy cuts cardiovascular event risk by over half vs tirzepatide—real-world data raises Novo Nordisk lead
Discover how Novo Nordisk’s Wegovy reduced heart attack, stroke, and death risk by 57% vs tirzepatide in real-world study. Read the STEER findings now.
Can dual agonist drugs like amycretin and tirzepatide replace bariatric surgery by 2030?
Can new obesity drugs like amycretin and tirzepatide replace bariatric surgery by 2030? Discover what clinical data and cost trends reveal about the future.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.
Hims & Hers’ earnings soar while GLP-1 drug crisis deepens—what this means for investors
Hims & Hers Health Inc. saw its stock surge following a robust quarterly earnings report, which showcased significant…